{ "run": { "id": "cmnr15kha073ap6588z058axx", "region": "US", "assetId": "cmnr15kgz0736p658726rhqcz", "ticker": "WST", "snapshotId": "cmnr15kh40738p658c7wxols6", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:22:10.028Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15kh40738p658c7wxols6", "assetId": "cmnr15kgz0736p658726rhqcz", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 262.76, "price": 265.93, "dayLow": 262.03, "volume": 689413, "dayHigh": 266.73, "currency": "USD", "prevClose": 259.35, "week52Low": 187.43, "week52High": 322.34 }, "fundamentals": { "pe": 40.2840409956076, "beta": 0.893043390182542, "epsTTM": 6.83, "fcfTTM": 607200000, "growth": { "epsYoy": 0.01185185185185186, "revenueYoy": 0.06252592285358773 }, "sector": "Surgical & Medical Instruments & Apparatus", "margins": { "net": 0.1605998503627078, "gross": 0.3591295013174587, "operating": 0.1902670700367587 }, "website": "https://westpharma.com", "industry": "Medical devices", "pegRatio": 33.9896595900441, "ebitdaTTM": 636800000, "forwardPe": 34.3067331670823, "marketCap": 15700000000, "totalCash": 791300000, "totalDebt": 202800000, "debtEquity": 0.0638539042821159, "quickRatio": 2.085356542983662, "revenueTTM": 3074100000, "companyName": "WEST PHARMACEUTICAL SERVICES INC", "priceToBook": 6.26342002518892, "currentRatio": 3.020613834173156, "dividendYield": 0.00311170644070953, "returnOnAssets": 0.1156206088992974, "returnOnEquity": 0.155447103274559, "analystOpinions": null, "businessSummary": "West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.", "enterpriseValue": 19304122000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 8200, "sharesOutstanding": 72021491, "enterpriseToEbitda": 30.31426193467337, "analystTargetMedian": null, "enterpriseToRevenue": 6.279601184086399, "operatingCashflowTTM": 754800000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:22:10.024Z" }, "results": [ { "id": "cmnr15khd073cp658l0v89ysy", "runId": "cmnr15kha073ap6588z058axx", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"WST\",\"currency\":\"USD\",\"current_price\":265.93,\"target_price_6m\":272,\"target_price_12m\":278,\"recommendation\":\"HOLD\",\"confidence\":0.65,\"thesis_bullets\":[\"High-quality pharma packaging business with strong competitive moat\",\"Premium valuation at 40x P/E limits upside despite quality\",\"Modest EPS growth of ~1% YoY does not support current multiple\",\"Strong balance sheet with net cash and 3x current ratio\",\"Biologics and GLP-1 tailwinds provide medium-term revenue support\"],\"key_drivers\":[{\"driver\":\"Biologics and GLP-1 drug delivery demand growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation leaves limited margin of safety\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Very low debt/equity (6.4%) provides financial flexibility\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion potential toward 21%\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Slowing EPS growth (~1% YoY) vs elevated P/E\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"PEG ratio of 34x signals growth not priced efficiently\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Customer concentration in top pharma companies\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation ($607M TTM) supports buybacks/dividends\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Multiple compression if growth stays below mid-single digits\",\"Customer destocking cycles could impact near-term revenue\",\"Rising competition from alternative drug delivery systems\",\"Tariff or supply chain disruptions on elastomer/rubber inputs\",\"GLP-1 demand normalization could slow packaging volume growth\",\"FX headwinds given global manufacturing footprint\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.205,\"wacc\":0.085,\"terminal_multiple\":28},\"scenarios\":{\"bear\":{\"target_price\":230,\"prob\":0.25,\"notes\":\"Multiple compresses to ~32x forward on persistent low-single-digit EPS growth.\"},\"base\":{\"target_price\":275,\"prob\":0.50,\"notes\":\"Modest margin expansion and mid-single-digit revenue growth sustain ~35x forward P/E.\"},\"bull\":{\"target_price\":310,\"prob\":0.25,\"notes\":\"Accelerating biologics demand drives high-single-digit EPS growth, re-rating to 38x forward.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA approach anchored on ~$7.50 forward EPS. At 37x forward P/E, fair value ~$278. Probability-weighted scenario value ~$273 supports HOLD. Premium quality offset by rich valuation and tepid near-term growth. PEG of 34x highlights growth-valuation disconnect. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Multiple compression if growth stays below mid-single digits", "Customer destocking cycles could impact near-term revenue", "Rising competition from alternative drug delivery systems", "Tariff or supply chain disruptions on elastomer/rubber inputs", "GLP-1 demand normalization could slow packaging volume growth", "FX headwinds given global manufacturing footprint" ], "ticker": "WST", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest margin expansion and mid-single-digit revenue growth sustain ~35x forward P/E.", "target_price": 275 }, "bear": { "prob": 0.25, "notes": "Multiple compresses to ~32x forward on persistent low-single-digit EPS growth.", "target_price": 230 }, "bull": { "prob": 0.25, "notes": "Accelerating biologics demand drives high-single-digit EPS growth, re-rating to 38x forward.", "target_price": 310 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 28, "ebit_margin_target": 0.205 }, "key_drivers": [ { "driver": "Biologics and GLP-1 drug delivery demand growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Premium valuation leaves limited margin of safety", "impact": "HIGH", "direction": "NEG" }, { "driver": "Very low debt/equity (6.4%) provides financial flexibility", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion potential toward 21%", "impact": "MED", "direction": "POS" }, { "driver": "Slowing EPS growth (~1% YoY) vs elevated P/E", "impact": "HIGH", "direction": "NEG" }, { "driver": "PEG ratio of 34x signals growth not priced efficiently", "impact": "MED", "direction": "NEG" }, { "driver": "Customer concentration in top pharma companies", "impact": "MED", "direction": "NEG" }, { "driver": "Strong FCF generation ($607M TTM) supports buybacks/dividends", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended forward P/E and EV/EBITDA approach anchored on ~$7.50 forward EPS. At 37x forward P/E, fair value ~$278. Probability-weighted scenario value ~$273 supports HOLD. Premium quality offset by rich valuation and tepid near-term growth. PEG of 34x highlights growth-valuation disconnect. Not investment advice.", "current_price": 265.93, "recommendation": "HOLD", "thesis_bullets": [ "High-quality pharma packaging business with strong competitive moat", "Premium valuation at 40x P/E limits upside despite quality", "Modest EPS growth of ~1% YoY does not support current multiple", "Strong balance sheet with net cash and 3x current ratio", "Biologics and GLP-1 tailwinds provide medium-term revenue support" ], "target_price_6m": 272, "target_price_12m": 278 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35061, "createdAt": "2026-04-09T05:22:10.028Z", "usage": { "inputTokens": 3609, "outputTokens": 1722, "costUsd": 0.061095 } }, { "id": "cmnr15khd073fp65824288gou", "runId": "cmnr15kha073ap6588z058axx", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research V1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"WST\",\n \"currency\": \"USD\",\n \"current_price\": 265.93,\n \"target_price_6m\": 240.0,\n \"target_price_12m\": 230.0,\n \"recommendation\": \"SELL\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"High P/E and PEG ratios indicate overvaluation.\",\n \"Modest revenue and EPS growth in recent periods.\",\n \"Strong balance sheet with low debt and good liquidity.\",\n \"Medical device sector faces intense competition.\",\n \"Valuation disconnect from growth fundamentals.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth acceleration\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"EBITDA margin improvement\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals for new products\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Pricing pressure from customers\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Innovation in injectable systems\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Healthcare policy changes\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Macroeconomic factors affecting spending\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Economic recession reducing drug development\",\n \"Increased competition eroding market share\",\n \"Supply chain disruptions affecting production\",\n \"Adverse currency movements impacting international sales\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.20,\n \"wacc\": 0.08,\n \"terminal_multiple\": 25.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 200.0, \"prob\": 0.3, \"notes\": \"Lower growth and multiple compression.\" },\n \"base\": { \"target_price\": 230.0, \"prob\": 0.5, \"notes\": \"Base case with moderate assumptions.\" },\n \"bull\": { \"target_price\": 260.0, \"prob\": 0.2, \"notes\": \"Higher growth and margin expansion.\" }\n },\n \"method_notes\": \"Valuation based on DCF with 8% revenue CAGR, 20% EBIT margin, 8% WACC, 25x terminal multiple. SELL due to -13.5% expected 12M return. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research V1", "risks": [ "Economic recession reducing drug development", "Increased competition eroding market share", "Supply chain disruptions affecting production", "Adverse currency movements impacting international sales" ], "ticker": "WST", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Base case with moderate assumptions.", "target_price": 230 }, "bear": { "prob": 0.3, "notes": "Lower growth and multiple compression.", "target_price": 200 }, "bull": { "prob": 0.2, "notes": "Higher growth and margin expansion.", "target_price": 260 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.08, "terminal_multiple": 25, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Revenue growth acceleration", "impact": "MED", "direction": "POS" }, { "driver": "EBITDA margin improvement", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory approvals for new products", "impact": "HIGH", "direction": "POS" }, { "driver": "Pricing pressure from customers", "impact": "MED", "direction": "NEG" }, { "driver": "Innovation in injectable systems", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare policy changes", "impact": "LOW", "direction": "NEG" }, { "driver": "Macroeconomic factors affecting spending", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with 8% revenue CAGR, 20% EBIT margin, 8% WACC, 25x terminal multiple. SELL due to -13.5% expected 12M return. Not investment advice.", "current_price": 265.93, "recommendation": "SELL", "thesis_bullets": [ "High P/E and PEG ratios indicate overvaluation.", "Modest revenue and EPS growth in recent periods.", "Strong balance sheet with low debt and good liquidity.", "Medical device sector faces intense competition.", "Valuation disconnect from growth fundamentals." ], "target_price_6m": 240, "target_price_12m": 230 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 333, "createdAt": "2026-04-09T05:22:10.028Z", "usage": { "inputTokens": 2120, "outputTokens": 3893, "costUsd": 0.002229 } }, { "id": "cmnr15khd073dp658gzep19fa", "runId": "cmnr15kha073ap6588z058axx", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_WST_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"WST\",\n \"currency\": \"USD\",\n \"current_price\": 265.93,\n \"target_price_6m\": 262.0,\n \"target_price_12m\": 260.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Dominant market share in injectable packaging provides a wide moat and strong pricing power.\",\n \"GLP-1 drug adoption offers a significant long-term tailwind for high-value proprietary components.\",\n \"Post-COVID inventory destocking continues to weigh heavily on near-term revenue and EPS growth.\",\n \"Valuation is stretched at ~40x trailing P/E, leaving little room for execution missteps.\",\n \"Strong balance sheet with net cash position supports share buybacks and dividend growth.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"GLP-1 drug volume growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Customer inventory destocking\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Proprietary products mix shift\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Raw material cost inflation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Biologics pipeline approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Capacity expansion capex\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Currency exchange fluctuations\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged customer destocking delaying revenue re-acceleration.\",\n \"Shift from injectable to oral formulations for GLP-1 and other biologics.\",\n \"Multiple contraction if high-single-digit growth expectations are not met.\",\n \"Supply chain disruptions affecting specialized raw material availability.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.075,\n \"terminal_multiple\": 25.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 210.0,\n \"prob\": 0.25,\n \"notes\": \"Destocking persists and GLP-1 oral alternatives gain traction, causing multiple contraction.\"\n },\n \"base\": {\n \"target_price\": 260.0,\n \"prob\": 0.55,\n \"notes\": \"Destocking normalizes and steady high-single-digit growth resumes, but valuation limits upside.\"\n },\n \"bull\": {\n \"target_price\": 310.0,\n \"prob\": 0.2,\n \"notes\": \"Explosive GLP-1 demand drives rapid margin expansion and sustains a premium >35x P/E multiple.\"\n }\n },\n \"method_notes\": \"DCF and EV/EBITDA multiple valuation. Base case assumes 8% revenue CAGR and 25x terminal multiple. High valuation limits upside, resulting in a HOLD recommendation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearch_WST_v1", "risks": [ "Prolonged customer destocking delaying revenue re-acceleration.", "Shift from injectable to oral formulations for GLP-1 and other biologics.", "Multiple contraction if high-single-digit growth expectations are not met.", "Supply chain disruptions affecting specialized raw material availability." ], "ticker": "WST", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Destocking normalizes and steady high-single-digit growth resumes, but valuation limits upside.", "target_price": 260 }, "bear": { "prob": 0.25, "notes": "Destocking persists and GLP-1 oral alternatives gain traction, causing multiple contraction.", "target_price": 210 }, "bull": { "prob": 0.2, "notes": "Explosive GLP-1 demand drives rapid margin expansion and sustains a premium >35x P/E multiple.", "target_price": 310 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.08, "terminal_multiple": 25, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "GLP-1 drug volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Customer inventory destocking", "impact": "HIGH", "direction": "NEG" }, { "driver": "Proprietary products mix shift", "impact": "MED", "direction": "POS" }, { "driver": "Raw material cost inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Biologics pipeline approvals", "impact": "MED", "direction": "POS" }, { "driver": "Capacity expansion capex", "impact": "LOW", "direction": "POS" }, { "driver": "Currency exchange fluctuations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF and EV/EBITDA multiple valuation. Base case assumes 8% revenue CAGR and 25x terminal multiple. High valuation limits upside, resulting in a HOLD recommendation. Not investment advice.", "current_price": 265.93, "recommendation": "HOLD", "thesis_bullets": [ "Dominant market share in injectable packaging provides a wide moat and strong pricing power.", "GLP-1 drug adoption offers a significant long-term tailwind for high-value proprietary components.", "Post-COVID inventory destocking continues to weigh heavily on near-term revenue and EPS growth.", "Valuation is stretched at ~40x trailing P/E, leaving little room for execution missteps.", "Strong balance sheet with net cash position supports share buybacks and dividend growth." ], "target_price_6m": 262, "target_price_12m": 260 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 23488, "createdAt": "2026-04-09T05:22:10.028Z", "usage": { "inputTokens": 2483, "outputTokens": 885, "costUsd": 0.015586 } }, { "id": "cmnr15khd073bp658caw53qtw", "runId": "cmnr15kha073ap6588z058axx", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"WST\",\"currency\":\"USD\",\"current_price\":265.93,\"target_price_6m\":248,\"target_price_12m\":238,\"recommendation\":\"SELL\",\"confidence\":0.62,\"thesis_bullets\":[\"High-quality injectable packaging franchise with sticky pharma customer relationships.\",\"Biologics and GLP-1 exposure support steady underlying volume growth.\",\"Near-term EPS growth is muted versus a still-demanding valuation.\",\"Current multiples imply stronger margin expansion than fundamentals currently support.\",\"Balance-sheet strength limits downside, but expected 12M return remains negative.\"],\"key_drivers\":[{\"driver\":\"Biologics component demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 device adoption\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High-value product mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Destocking normalization pace\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Multiple compression risk\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Large-customer order volatility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Margin recovery execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Regulatory switching costs\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Faster GLP-1 and biologics ramp.\",\"Quicker margin recovery than modeled.\",\"Acquisition or capital deployment upside.\",\"Quality or supply disruptions.\",\"Customer inventory swings.\"],\"assumptions\":{\"revenue_cagr_3y\":0.065,\"ebit_margin_target\":0.22,\"wacc\":0.083,\"terminal_multiple\":23},\"scenarios\":{\"bear\":{\"target_price\":205,\"prob\":0.25,\"notes\":\"Volumes stay soft and the premium multiple compresses further.\"},\"base\":{\"target_price\":238,\"prob\":0.55,\"notes\":\"Growth continues, but valuation derates toward quality medtech peers.\"},\"bull\":{\"target_price\":280,\"prob\":0.2,\"notes\":\"GLP-1 and biologics mix accelerate and margins rebound faster.\"}},\"method_notes\":\"Snapshot quote/fundamentals used as authoritative. Valuation based on quality-medtech earnings/EV-EBIT normalization, not sell-side targets; weighted 12M outcome implies >6% downside, supporting SELL. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "OpenAI o3", "risks": [ "Faster GLP-1 and biologics ramp.", "Quicker margin recovery than modeled.", "Acquisition or capital deployment upside.", "Quality or supply disruptions.", "Customer inventory swings." ], "ticker": "WST", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Growth continues, but valuation derates toward quality medtech peers.", "target_price": 238 }, "bear": { "prob": 0.25, "notes": "Volumes stay soft and the premium multiple compresses further.", "target_price": 205 }, "bull": { "prob": 0.2, "notes": "GLP-1 and biologics mix accelerate and margins rebound faster.", "target_price": 280 } }, "confidence": 0.62, "assumptions": { "wacc": 0.083, "revenue_cagr_3y": 0.065, "terminal_multiple": 23, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Biologics component demand", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 device adoption", "impact": "MED", "direction": "POS" }, { "driver": "High-value product mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Destocking normalization pace", "impact": "MED", "direction": "POS" }, { "driver": "Multiple compression risk", "impact": "HIGH", "direction": "NEG" }, { "driver": "Large-customer order volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Margin recovery execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory switching costs", "impact": "MED", "direction": "POS" } ], "method_notes": "Snapshot quote/fundamentals used as authoritative. Valuation based on quality-medtech earnings/EV-EBIT normalization, not sell-side targets; weighted 12M outcome implies >6% downside, supporting SELL. not investment advice", "current_price": 265.93, "recommendation": "SELL", "thesis_bullets": [ "High-quality injectable packaging franchise with sticky pharma customer relationships.", "Biologics and GLP-1 exposure support steady underlying volume growth.", "Near-term EPS growth is muted versus a still-demanding valuation.", "Current multiples imply stronger margin expansion than fundamentals currently support.", "Balance-sheet strength limits downside, but expected 12M return remains negative." ], "target_price_6m": 248, "target_price_12m": 238 }, "errorsJson": { "attempts": [ { "error": "sanity_error: sell_scenario_return_not_negative_enough: SELL requires <= -6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"WST\",\"currency\":\"USD\",\"current_price\":265.93,\"target_price_6m\":253,\"target_price_12m\":249,\"recommendation\":\"SELL\",\"confidence\":0.63,\"thesis_bullets\":[\"Premium pharma packaging franchise with sticky relationships and high regulatory switching costs.\",\"Biologics, self-injection, and GLP-1 formats support durable mid-single-digit demand.\",\"Margins should recover as mix improves and destocking headwinds fade.\",\"Valuation remains demanding at ~34x forward earnings despite muted near-term EPS growth.\",\"Quality and balance sheet limit downside, but upside looks capped over 12 months.\"],\"key_drivers\":[{\"driver\":\"Biologics and GLP-1 component demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"High-value product mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Destocking normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin recovery execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Valuation multiple compression\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Large-customer order volatility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory switching costs/moat\",\"impact\":\"MED\",\"direction\":\"POS\"},{…" } ], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_036626cfb7cc92e00069d75f1d61a08193adc133fbf5401782", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 17132, "createdAt": "2026-04-09T05:22:10.028Z", "usage": { "inputTokens": 2927, "outputTokens": 965, "costUsd": 0.018632 } }, { "id": "cmnr15khd073ep658km7dzszy", "runId": "cmnr15kha073ap6588z058axx", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"WST\",\n \"currency\": \"USD\",\n \"current_price\": 265.93,\n \"target_price_6m\": 272,\n \"target_price_12m\": 280,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Market leader in pharma injectable packaging\",\n \"Tailwinds from biologics and GLP-1 therapies\",\n \"Strong margins and low-debt balance sheet\",\n \"Elevated PE and PEG ratio limit upside\",\n \"Modest recent growth adds execution risk\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biologics and GLP-1 demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Innovation in delivery systems\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Revenue growth trajectory\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin trends\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High current valuation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory approval delays\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competition from peers\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Macro healthcare spending\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Slowdown in biologics demand\",\n \"Market share erosion to competitors\",\n \"Raw material cost inflation\",\n \"Regulatory changes for devices\",\n \"Multiple contraction in medtech\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.075,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.09,\n \"terminal_multiple\": 32\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 210,\n \"prob\": 0.3,\n \"notes\": \"Growth slows and margins contract from competition.\"\n },\n \"base\": {\n \"target_price\": 280,\n \"prob\": 0.5,\n \"notes\": \"Steady growth with stable margins at current valuation.\"\n },\n \"bull\": {\n \"target_price\": 350,\n \"prob\": 0.2,\n \"notes\": \"Accelerated demand drives beats and multiple expansion.\"\n }\n },\n \"method_notes\": \"DCF using 7.5% revenue CAGR, 20% EBIT margin, 9% WACC and 32x terminal. Rich valuation and mixed growth yield limited upside. not investment advice\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "Slowdown in biologics demand", "Market share erosion to competitors", "Raw material cost inflation", "Regulatory changes for devices", "Multiple contraction in medtech" ], "ticker": "WST", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth with stable margins at current valuation.", "target_price": 280 }, "bear": { "prob": 0.3, "notes": "Growth slows and margins contract from competition.", "target_price": 210 }, "bull": { "prob": 0.2, "notes": "Accelerated demand drives beats and multiple expansion.", "target_price": 350 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.075, "terminal_multiple": 32, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Biologics and GLP-1 demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Innovation in delivery systems", "impact": "MED", "direction": "POS" }, { "driver": "Revenue growth trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin trends", "impact": "MED", "direction": "POS" }, { "driver": "High current valuation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory approval delays", "impact": "MED", "direction": "NEG" }, { "driver": "Competition from peers", "impact": "MED", "direction": "NEG" }, { "driver": "Macro healthcare spending", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF using 7.5% revenue CAGR, 20% EBIT margin, 9% WACC and 32x terminal. Rich valuation and mixed growth yield limited upside. not investment advice", "current_price": 265.93, "recommendation": "HOLD", "thesis_bullets": [ "Market leader in pharma injectable packaging", "Tailwinds from biologics and GLP-1 therapies", "Strong margins and low-debt balance sheet", "Elevated PE and PEG ratio limit upside", "Modest recent growth adds execution risk" ], "target_price_6m": 272, "target_price_12m": 280 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "d05f172f-3a95-9b8e-893d-0f5c892053bb", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 24452, "createdAt": "2026-04-09T05:22:10.028Z", "usage": { "inputTokens": 2729, "outputTokens": 3834, "costUsd": 0.065697 } } ] } }